Article: Tips for successful editing in T cells
Gene editing by CRISPR has led to significant advances in immunotherapy development. CRISPR can be used to rapidly knock out cell surface receptors, thereby limiting concerns of rejection by the immune system if the T cells engineered were not collected from the recipient. CRISPR also offers the ability to knock-in specific sequences into any gene, including chimeric antigen receptors (CARs) which target activated T cells to a specific tumor recognition site.
Related content from this organisation
- CRISPR screening to identify new drug targets in regulatory B cells and other immune cells
- Genetic screening to predict the risk of future diseases
- Antimicrobial resistance – a public health emergency on the horizon
- Screening In-Depth Focus 2020
- Application note: 3D cell panel screens for drug discovery and development